Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis in susceptible bacteria.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment of serious infections caused by susceptible gram-negative bacteria,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burns,Off-label: Bacterial endocarditis prophylaxis,Off-label: Intraocular injection for endophthalmitis
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
1-2 mg/kg IV every 8 hours, adjusted based on serum concentrations and creatinine clearance.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged to 24-48 hours in anuric patients requiring dose adjustment.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Gentamicin is not significantly metabolized; it is excreted primarily unchanged by glomerular filtration.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: >90% unchanged via glomerular filtration; biliary: <2%; fecal: negligible.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
<30% bound primarily to albumin; low binding reduces displacement interactions.
Low protein binding; 0–11% bound, primarily to albumin.
0.2-0.3 L/kg; approximates extracellular fluid volume; increased in edema, ascites, or burns.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intramuscular: ~100%; topical: minimal systemic absorption (<1%); intravenous: 100% (by definition).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Cr Cl 60-90 m L/min: 1.7 mg/kg every 12 hours; Cr Cl 40-59 m L/min: 1.7 mg/kg every 24 hours; Cr Cl 20-39 m L/min: 1.7 mg/kg as a single dose then adjust based on serum levels; Cr Cl <20 m L/min: 1.7 mg/kg as a single dose then redose based on serum levels; Hemodialysis: 1-2 mg/kg after dialysis with supplemental dosing based on serum levels.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No dose adjustment required for hepatic impairment; gentamicin is primarily renally eliminated.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Neonates (<7 days): 4-5 mg/kg IV every 24-36 hours; Infants >7 days: 2.5 mg/kg IV every 8 hours; Children: 2-2.5 mg/kg IV every 8 hours; adjust based on serum concentrations and renal function.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Dose adjustment based on renal function; calculate Cr Cl using Cockcroft-Gault equation with ideal body weight; typical starting dose: 1-1.7 mg/kg IV every 8-12 hours, with subsequent dosing guided by serum concentrations.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
WARNING: OTOTOXICITY AND NEPHROTOXICITY. Gentamicin can cause ototoxicity (vestibular and auditory) and nephrotoxicity. Risk increases with prolonged use, high doses, renal impairment, and advanced age. Monitor renal function and auditory function regularly.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Neurotoxicity including ototoxicity and nephrotoxicity,Neuromuscular blockade leading to respiratory paralysis,Superinfection with resistant organisms,May worsen weakness in myasthenia gravis or Parkinson's disease,Use with caution in premature infants and neonates due to renal immaturity,Monitor serum drug levels to avoid toxicity
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to gentamicin or other aminoglycosides,Severe renal disease with anuria (relative contraindication; use only if benefits outweigh risks)
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No significant food interactions. Avoid excessive potassium intake if renal impairment.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Gentamicin is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. First trimester: Avoid unless essential due to potential for ototoxicity and nephrotoxicity. Second and third trimesters: Use only for severe infections when alternative antibiotics are not available. Risk of fetal inner ear damage and renal impairment associated with aminoglycosides.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Gentamicin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.15-0.2. Oral bioavailability in infants is poor, minimizing systemic absorption. However, potential for disruption of infant gut flora and direct irritation. Use with caution, especially in neonates with immature renal function. Monitor infant for diarrhea or rash.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Increased volume of distribution and enhanced renal clearance during pregnancy may necessitate higher doses or more frequent administration to achieve therapeutic serum levels. Therapeutic drug monitoring is recommended. Initial dosing based on ideal body weight and renal function; adjust to maintain target peak (6-10 mcg/m L) and trough (<2 mcg/m L) concentrations.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Monitor peak (30 min after 30-min infusion) and trough (just before next dose) levels; target peak 5-10 mcg/m L, trough <2 mcg/m L. Adjust dose in renal impairment. Avoid concurrent ototoxic/nephrotoxic drugs. Consider once-daily dosing for synergy with beta-lactams. Assess for vestibular toxicity with Romberg test.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Report any hearing loss, ringing in ears, dizziness, or balance problems immediately.,Drink plenty of fluids unless instructed otherwise by your doctor.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.,This medication is given intravenously; do not mix with other drugs in the same line without pharmacy approval.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Gentamicin, an aminoglycoside antibiotic, and Amphotericin B, a polyene antifungal agent, both independently induce nephrotoxicity. Concurrent administration synergistically increases the risk of acute kidney injury, characterized by elevated serum creatinine, reduced glomerular filtration rate, and potential tubular necrosis. This additive nephrotoxic effect necessitates cautious use and enhanced monitoring."
"Pamidronic acid, a bisphosphonate, inhibits osteoclast-mediated bone resorption, reducing serum calcium levels. Gentamicin, an aminoglycoside antibiotic, can cause renal tubular injury, impairing the kidney's ability to reabsorb calcium and leading to hypocalcemia. Concurrent use increases the risk of severe, symptomatic hypocalcemia, potentially manifesting as tetany, arrhythmias, or seizures."
"Gentamicin and foscarnet both have nephrotoxic potential, and concurrent use can lead to additive or synergistic renal injury. This interaction increases the risk of acute kidney injury, particularly in patients with pre-existing renal impairment or volume depletion, and may result in reduced glomerular filtration rate and elevated serum creatinine."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis in susceptible bacteria.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 1-2 mg/kg IV every 8 hours, adjusted based on serum concentrations and creatinine clearance.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Gentamicin is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.